Arkolith/Insider Trading/KALV/Form 4

Piekos Brian

Chief Financial OfficerKalVista Pharmaceuticals, Inc. (KALV) · full profile →Form 4 · filed Jun 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 11, 2026Disposed to issuer(D)22K—$00

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 11, 2026Disposed to issuer(D)100K——0
Jun 11, 2026Disposed to issuer(D)55K——0
Jun 11, 2026Disposed to issuer(D)94K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001815308-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML